Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2008-05-11 Director's Dealing
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the interest, and transaction details. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions (insider trades). This matches the definition of 'Director's Dealing' filings.
2008-05-11 English
Results of Meeting 5 pages ?Kb
AGM Information Classification · 100% confidence The document is titled as the minutes of the 2nd Annual General Meeting (AGM) of Cyclopharm Limited held on 1 May 2008. It includes details typical of AGM minutes such as attendance, proxies, resolutions passed, adoption of financial statements, remuneration report, election of directors, dividend reinvestment plan approval, and questions from shareholders. The content is focused on the proceedings and decisions made during the AGM rather than presenting the full annual report or financial statements themselves. The presence of proxy voting results and formal resolutions further confirms this is an AGM minutes document. Therefore, the document fits the category of AGM Information (AGM-R). The document length (9160 characters) and detailed meeting content support this classification with high confidence.
2008-05-01 English
AGM Presentation 34 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Cyclopharm Limited Annual General Meeting 1 May 2008' and contains agenda items typical of an AGM, including a Chairman's welcome, Managing Director's review, proxy summary with voting results, and business highlights. It includes detailed financial analysis and business initiatives, but the context and structure indicate it is presentation material or minutes from an Annual General Meeting rather than a full annual report or standalone financial report. The presence of proxy voting results and the format focusing on the meeting agenda and shareholder engagement strongly suggest this is AGM Information. The document length (12,919 characters) supports it being a detailed AGM presentation or minutes rather than a brief announcement or a full 10-K report. Therefore, the most appropriate classification is AGM Information (AGM-R).
2008-05-01 English
Change in substantial holding 3 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 notice under the Corporations Act 2001, which reports changes in interests of a substantial holder in a company (Cyclopharm Limited). It details changes in voting power, relevant interests, and share purchases by the substantial holder Chemical Trustee Limited. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of shareholding changes.
2008-04-27 English
Amended Appendix 3Y released 25 March 2008 3 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and the value of the transaction. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, management discussion, or other report types. Therefore, it fits the definition of 'Director's Dealing' (DIRS). The document length is 2811 characters, which is consistent with a notice rather than a full report or announcement of a report. Hence, the classification is DIRS with high confidence.
2008-04-01 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and dates of the transactions. It also includes a section on changes in contracts related to the director's interests, which are noted as nil. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or other report types. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is 3151 characters, which is consistent with a detailed insider trading notice rather than a full report or announcement. Confidence in this classification is high.
2008-04-01 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.